Evaluating the Value of a Payer Contract

Published in Government Relations on June 24, 2025

By Melanie Ewald, VP of Payer Relations and Reimbursement, VGM  

In our last article, Key Payers Denied Your Application Citing Their Network Is Closed – Now What?, we discussed strategies for addressing payer contracting denials due to a closed network. As indicated, this process can be an extremely time-consuming exercise with no guarantees and mixed results. Below are a few things to consider as you evaluate whether a contract is worth the extra effort. 

DMEPOS providers continue to navigate a minefield of challenges such as shrinking margins, regulatory complexities, and challenges with payer reimbursement and contracting. Deciding whether to enter or remain in-network with a given payer is one of the most critical decisions DME providers will make. Getting in-network under the right contract can expand access to more patients and thus increase revenue.  

Entering or remaining in the wrong contract can chip away at your profitability. You are not required to accept every contract offered to you. Consider the following as you evaluate new and existing contract opportunities. 

Does the contract bring in new patients? Does it increase your ability to say “Yes” more often to referral sources? Are you getting paid more than what you paid to acquire the product? Do you require profit on every transaction? Each of these points is important on their own; however, even when combined, they do not necessarily make a contract worth having or viable.  

Viable long-term contracts provide for at least the following: 

  • Reimbursement covers ALL costs, not just product acquisition. 
  • Policies are actually followed as prescribed in the contract and provider manuals. 
  • Transparent notice process for contract amendments and policy updates. 
  • Clearly defined resolution process for when issues arise. 

Pay close attention to arrangements that may have hidden profit diminishers such as: 

  • Administratively burdensome requirements that increase your costs. i.e., employee time required to handle frequent prior authorizations and denial management due to unclear documentation requirements and unclear appeals processes. 
  • High volume low-reimbursement arrangements may provide access to more patients, but will not fix profit margins and may drain critical resources. 

Today’s payer environment is such that not every contract is worth having and some could ultimately be detrimental to your business. Each contract, particularly those requiring extensive effort and resources to execute, should be evaluated closely with profitability, operational efficiency, and strategic fit in mind. 

From Our Experts

Proposed Rule Suggests Significant Change To Accreditation Process thumbnail Proposed Rule Suggests Significant Change To Accreditation Process The recently released proposed rule CMS-1828-P contains a significant change that could reshape how suppliers navigate accreditation. The rule proposes a major change that would require suppliers to be surveyed and reaccredited annually instead of the current three (3) year cadence. This proposal raises substantial questions about both operational feasibility and cost implications. August Of Action: Your Chance To Connect With Congress thumbnail August Of Action: Your Chance To Connect With Congress It's time to take advantage of August Of Action—a perfect opportunity to make your voice heard. Every summer, federal legislators return to their home states during the Congressional recess. While it gives them a break from Washington D.C., it's primarily a time for them to connect with constituents like you. HR1 Passes House, Advances to President Trump's Desk for Signature thumbnail HR1 Passes House, Advances to President Trump's Desk for Signature After extensive negotiations and partisan debate, the House has officially passed HR1, clearing the path for the bill to be signed into law by President Donald Trump. The legislation, which aims to reduce federal healthcare expenditures, contains several provisions that may impact the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) industry. CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program thumbnail CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program On June 30, 2025, CMS filed the anticipated Proposed Rule that includes updates to the Competitive Bidding Program (CBP). Public comments are due 60 days from June 30, 2025. Below is a high-level summary of the rule. It is critical to note that, according to the Proposed Rule Fact Sheet dated June 30, 2025, CMS has stated that they have not announced the specific product categories they are bidding or the specific timeframe for the next competition. Those specifics will be forthcoming in a fu Senate Narrowly Passes HR1, Sending It Back to House for Final Approval thumbnail Senate Narrowly Passes HR1, Sending It Back to House for Final Approval President Donald Trump's sweeping legislative package, formally titled the One Big, Beautiful Bill Act, now referred to as HR1., cleared the Senate today in a dramatic 51–50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill now returns to the House, where lawmakers must decide whether to adopt the Senate's revised version or negotiate further changes before it can reach the president's desk. Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule thumbnail Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule Senate Parliamentarian Elizabeth MacDonough advised this week that multiple Medicaid provisions in the Senate's reconciliation bill would violate Senate procedure by violating the Byrd Rule. The Byrd Rule is a Senate-specific procedural process that allows Senators to prevent or block inclusion of extraneous provisions in reconciliation bills. Other provisions are still under review. Webinar: Webinar: "Navigating The New CMS Landscape: RADs, HMVs, and Supplier Survival" on June 25 at 1 p.m. CT. The Centers for Medicare & Medicaid Services (CMS) has released its final National Coverage Determination (NCD) for RADs and HMVs used in treating chronic respiratory failure due to COPD. While the rule potentially expands access to bilevel ST therapy (RADs), it also introduces complex compliance requirements, tighter usage criteria, and increased documentation burdens—without additional reimbursement. The Return of Competitive Bidding thumbnail The Return of Competitive Bidding The Centers for Medicare & Medicaid Services (CMS) appear to be laying the groundwork for another round of the Competitive Bidding Program (CBP). While full implementation will take a couple of years, an official announcement is expected this summer—potentially as early as July.